Auris Formulations for Inner Ear Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inner ear diseases face challenges due to the blood-labyrinth-barrier, which limits drug delivery, and existing formulations lack stringent sterility, compatibility with the inner ear environment, and controlled release mechanisms, leading to inefficiencies and side effects.
Innovation Solution
Development of auris formulations that are sterilized, compatible with the inner ear's ionic balance, and provide controlled release of immunomodulating or aural pressure modulating agents, using polyoxyethylene-polyoxypropylene triblock copolymers and other additives to ensure safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations are used for inner ear treatment, then drug delivery is attempted, but the blood-labyrinth-barrier limits effective drug delivery to the inner ear
Solution Approach 1:
The patent uses intratympanic injection as an intermediary route to deliver drugs directly into the middle ear space, bypassing the blood-labyrinth-barrier. The formulation includes penetration enhancers that act as mediators to facilitate drug transfer across the tympanic membrane into the inner ear, overcoming the barrier limitation without requiring systemic circulation.
Solution Approach 2:
The patent segments the drug delivery system into multiple functional components: the active pharmaceutical ingredient, penetration enhancers to cross the tympanic membrane, and sustained-release polymers to control drug release kinetics. This segmentation allows each component to address specific challenges in overcoming the blood-labyrinth-barrier and maintaining therapeutic levels.
2Reliability
If existing formulations are administered to the inner ear, then treatment is provided, but sterility requirements are not met leading to infection risk in the isolated inner ear environment
Solution Approach 1:
The patent creates a sterile, pyrogen-free formulation environment that mimics the isolated nature of the inner ear. The formulation undergoes stringent sterilization processes and includes preservatives to maintain an inert, infection-free state, protecting the vulnerable inner ear environment from microbial contamination during and after administration.
Solution Approach 2:
The patent incorporates preservatives and sterilization steps before administration to prevent infection. The formulation is prepared with antimicrobial agents and undergoes sterilization processes in advance to cushion against potential infection risks, protecting the inner ear before any microbial exposure can occur.
3Reliability
If conventional formulations are used, then drug is delivered, but the formulations are not compatible with the inner ear's ionic balance causing physiological disruption
Solution Approach 1:
The patent modifies the formulation parameters to match inner ear physiology. The pH is adjusted to be compatible with endolymph and perilymph, osmolarity is matched to prevent fluid shifts, and ionic composition is tailored to maintain the delicate ionic balance of the inner ear environment while still enabling effective drug delivery.
4Reliability
If multiple administrations are required for treatment, then therapeutic effect is maintained, but patient discomfort and treatment complexity increase
Solution Approach 1:
The patent employs sustained-release polymers that provide continuous drug release over extended periods after a single intratympanic injection. This continuous release mechanism maintains therapeutic drug levels in the inner ear without requiring multiple administrations, eliminating the need for repeated patient visits and injections while ensuring consistent therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations achieve targeted and sustained drug delivery with reduced systemic toxicity, improved therapeutic index, and extended exposure to the inner ear, minimizing discomfort and side effects while maintaining sterility and compatibility with the inner ear environment.
Implementation Method 1
controlled release formulations... provide a constant, sustained, extended, delayed or pulsatile rate of release of an active agent
Implementation Method 2
The formulations described herein comprise polymers that are biodegradable and/or dispersable
Implementation Method 3
osmolarity/osmolality of the present formulations is adjusted... which renders the formulations endolymph-compatible and/or perilymph-compatible (i.e. isotonic with the endolymph and/or the perilymph)
Implementation Method 4
The blood-labyrinth-barrier (BLB), which includes a blood-endolymph barrier and a blood-perilymph barrier, consists of tight junctions between specialized epithelial cells in the labyrinth spaces
Data Source
AI summary
Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.